Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone818-629-2256
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees39
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable
Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions
What is Sienna Biopharmaceuticals' stock symbol?
Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."
How were Sienna Biopharmaceuticals' earnings last quarter?
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($0.93) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.83) by $0.10. View Sienna Biopharmaceuticals' Earnings History.
When is Sienna Biopharmaceuticals' next earnings date?
What price target have analysts set for SNNA?
2 brokers have issued twelve-month target prices for Sienna Biopharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Sienna Biopharmaceuticals' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 2,109.1% from the stock's current price. View Analyst Price Targets for Sienna Biopharmaceuticals.
What is the consensus analysts' recommendation for Sienna Biopharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sienna Biopharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sienna Biopharmaceuticals.
Has Sienna Biopharmaceuticals been receiving favorable news coverage?
Media coverage about SNNA stock has been trending very negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sienna Biopharmaceuticals earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Sienna Biopharmaceuticals.
Who are some of Sienna Biopharmaceuticals' key competitors?
Some companies that are related to Sienna Biopharmaceuticals include Neurotrope (NTRP), Correvio Pharma (CORV), BIOLINERX LTD/S (BLRX), Mateon Therapeutics (MATN), Heat Biologics (HTBX), Aytu Bioscience (AYTU), Novan (NOVN), Zosano Pharma (ZSAN), Conatus Pharmaceuticals (CNAT), IMMURON LTD/S (IMRN), Novelion Therapeutics (NVLN), Novelion Therapeutics (NVLNF), Diffusion Pharmaceuticals (DFFN), OTCMKTS:EMBI (EMBI) and Nemus Bioscience (NMUS).
What other stocks do shareholders of Sienna Biopharmaceuticals own?
Who are Sienna Biopharmaceuticals' key executives?
Sienna Biopharmaceuticals' management team includes the folowing people:
- Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 54)
- Mr. Timothy K. Andrews Esq., Gen. Counsel & Corp. Sec. (Age 40)
- Mr. Alexander Azoy, CFO & Controller (Age 43)
- Mr. Majed Kheir, VP of Operations (Age 41)
- Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 49)
When did Sienna Biopharmaceuticals IPO?
(SNNA) raised $64 million in an initial public offering (IPO) on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets served as the underwriters for the IPO.
How do I buy shares of Sienna Biopharmaceuticals?
Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sienna Biopharmaceuticals' stock price today?
One share of SNNA stock can currently be purchased for approximately $0.14.
How big of a company is Sienna Biopharmaceuticals?
Sienna Biopharmaceuticals has a market capitalization of $4.20 million. The company earns $-73,470,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Sienna Biopharmaceuticals employs 39 workers across the globe.View Additional Information About Sienna Biopharmaceuticals.
What is Sienna Biopharmaceuticals' official website?
How can I contact Sienna Biopharmaceuticals?
Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]
MarketBeat Community Rating for Sienna Biopharmaceuticals (NASDAQ SNNA)
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe SNNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
